TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 71492
Drug: Moderate-potency antilymphocyte
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-potency antilymphocyte globulin (A.L.G.)
Study: 6129872
Drug: Terfenadine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (2 X 60 mg/day)
Study: 6129872
Drug: Clemastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (2 X 1 mg/day)
Study: 23688096
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with vitamin E supplementation (200 mg every other day)
Study: 19901116
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg/d with antihypertensive prophylaxis
Study: 19901116
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg/d without antihypertensive prophylaxis
Study: 19901116
Drug: Cediranib 45
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 45 mg/d with antihypertensive prophylaxis
Study: 19901116
Drug: Cediranib 45
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 45 mg/d without antihypertensive prophylaxis
Study: 19901116
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (cediranib 30 or 45 mg/d with or without antihypertensive prophylaxis)
Study: 17320580
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of autologous blood infused in the pleural cavity (Group A)
Study: 17320580
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of autologous blood infused in the pleural cavity (Group B)
Study: 9459537
Drug: Anaerobic Threshold
Normalized name: Peptostreptococcus anaerobius
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaerobic Threshold at 4 mmol lactate x l(‐1) (AT4)
Study: 31221778
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs
Study: 2973485
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) plus immediate intervention (coronary angiography with a view to angioplasty)
Study: 1089874
Drug: Parenteral idoxuridine
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral idoxuridine at a dose of 100 mg per kilogram per day for five days
Study: 31238418
Drug: RIA-G software
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIA-G software
Study: 26241455
Drug: Dexamethasone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (30 mg total dose)
Study: 19299346
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of autologous blood alone (Group A)
Study: 19299346
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of lidocaine combined with peppering (Group B)
Study: 19299346
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of triamcinolone alone (Group C)
Study: 19299346
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of triamcinolone combined with peppering (Group D)
Study: 15065222
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (starting dose of 2 × 6 ml of a 40 mg/ml suspension, daily defined dose of 480 mg)
Study: 10100082
Drug: MDL 100,240
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDL 100,240 (6.25 mg and 25 mg doses)
Study: 1997185
Drug: Cis-diammine(glycolato)platinum (254-S)
Normalized name: cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-diammine(glycolato)platinum (254-S) at 50 mg/m2/120 h
Study: 1997185
Drug: Cis-diammine(glycolato)platinum (254-S)
Normalized name: cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2/120 h
Study: 1997185
Drug: Cis-diammine(glycolato)platinum (254-S)
Normalized name: cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-diammine(glycolato)platinum (254-S) at 100 mg/m2/120 h
Study: 1997185
Drug: Cis-diammine(glycolato)platinum (254-S)
Normalized name: cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-diammine(glycolato)platinum (254-S) at 87.5 mg/m2/120 h
Study: 1997185
Drug: Cis-diammine(glycolato)platinum (254-S)
Normalized name: cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)
DrugBank: Nedaplatin (DB13145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis-diammine(glycolato)platinum (254-S) at 75 mg/m2 or more
Study: 27521809
Drug: Extended-Release Naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-Release Naltrexone (XR-NTX)
Study: 1839144
Drug: Monthly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every month
Study: 1839144
Drug: Bimonthly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly treatment with ethinyl estradiol (30 micrograms/day) plus desogestrel (150 micrograms/day) in three-week cycles every other month
Study: 6222388
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg b.i.d. zimelidine
Study: 6222388
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg b.i.d. clomipramine
Study: 27175681
Drug: Essence of
Normalized name: ISOPROPYL ALCOHOL 70 mL in 100 mL TOPICAL GEL [The Essence of Eva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essence of Chicken (EC) 70 mL daily for 2 weeks
Study: 24585267
Drug: Diuretic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic response (Δ weight kg/40 mg furosemide)
Study: 24585267
Drug: Poor diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor diuretic response
Study: 16087825
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 mug once daily)
Study: 18003959
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg once daily)
Study: 11979503
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (250 mg day(-1))
Study: 11979503
Drug: Zinc (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (20 mg day(-1))
Study: 808195
Drug: Dextrose infusion
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose infusion
Study: 30144431
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg once daily for 6 months
Study: 26576619
Drug: Sodium polystyrene
Normalized name: Sodium Polystyrene Sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium polystyrene sulfonate (30 g orally once daily for 7 days)
Study: 23650803
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment group (acupuncture from the 7th to 14th day after surgery)
Study: 23650803
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment group (acupuncture from the 15th day after surgery)
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1200 microg every 4 weeks plus oral ribavirin
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 900 microg every 2 weeks plus oral ribavirin
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1200 microg every 2 weeks plus oral ribavirin
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1500 microg every 2 weeks plus oral ribavirin
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1800 microg every 2 weeks plus oral ribavirin
Study: 19061971
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b (various doses)
Study: 17029307
Drug: Mirtazapine 30-45
Normalized name: mirtazapine 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30-45 mg/day
Study: 10930159
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm (syndromic treatment)
Study: 9541340
Drug: Ibuprofen, 400
Normalized name: Ibuprofen, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen, 400 mg (n = 26)
Study: 31244686
Drug: Therapeutic Alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic Alliance Focused Therapy (TAFT)
Study: 28968793
Drug: SB4 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB4 (50 mg/week)
Study: 28968793
Drug: ETN (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETN (50 mg/week)
Study: 20837625
Drug: 5 monthly
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 monthly 60‐minute sessions at a recreation center (group physical activity, goal setting)
Study: 14498755
Drug: Pure ACE
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure ACE inhibitor
Study: 11012475
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 500 mg o.d. for 6 months
Study: 8816574
Drug: Copolymer‐1 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer‐1 (20 mg)
Study: 1287303
Drug: Pre-hospital thrombolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital thrombolysis with streptokinase (500,000 U) and heparin (10,000 U) administered before hospital admission (Group 1)
Study: 1287303
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Group 3)
Study: 1287303
Drug: Pre-hospital thrombolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital thrombolysis with streptokinase and heparin administered after hospital admission (Group 2)
Study: 3753988
Drug: Ciramadol 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciramadol 30 mg
Study: 30255760
Drug: N-Acetyl Cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetyl Cysteine (NAC) 600 mg twice daily for 12 weeks
Study: 29806738
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g powdered brown mustard
Study: 27663941
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Immunoglobulin (IVIG) 1 g/kg/day on 2 consecutive days
Study: 19346218
Drug: Commit nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commit nicotine lozenge (2 mg)
Study: 11965579
Drug: Interferon alfa‐2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b, 3 x 10(6) U three times weekly (Group B)
Study: 11965579
Drug: Interferon alfa‐2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b, 1 x 10(6) U/d, plus ribavirin, 400 mg twice daily (Group C)
Study: 10099140
Drug: Propranolol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol therapy (dose sufficient to decrease baseline heart rate by 25%)
Study: 10099140
Drug: Endoscopic variceal
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic variceal ligation (performed weekly until varices were obliterated)
Study: 2889528
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg
Study: 31363328
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risk factors (APACHE II >18, age >65, mechanical ventilation, sedation)
Study: 31363328
Drug: Sedation and
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation and previous antibiotic therapy
Study: 11309057
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of risk factors
Study: 21276671
Drug: Nasal Cannula
Normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Cannula (NC) group, weaned off NCPAP when FiO(2) was ≤0.30 to NC (2 L/min)
Study: 19351943
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT), n = 70
Study: 11747915
Drug: Fourth dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth dose of RTS,S/AS02
Study: 19924281
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (control)
Study: 31091508
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine
Study: 24597683
Drug: Integrated online
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated online psychosocial assessment and cognitive behavior therapy (CBT)
Study: 16456216
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR-MPH)
Study: 22314126
Drug: Osmotically controlled-release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotically controlled-release oral delivery system methylphenidate (OROS-MPH)
Study: 19000095
Drug: Rituximab (Rtx)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (Rtx) treatment
Study: 10510144
Drug: L‐758 298
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐758 298 (0.25 mg, 1 mg, 5 mg)
Study: 10510144
Drug: L‐758 298
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐758 298 (1.43 mg)
Study: 8526962
Drug: High fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fresh gas flow rate (6.0 L/min)
Study: 8526962
Drug: Minimal fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal fresh gas flow rate (0.6 L/min)
Study: 6790048
Drug: Intensive speech
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive speech therapy using slowed-speech and relaxation technique
Study: 6790048
Drug: Maintenance speech
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance speech therapy
Study: 29564507
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 mg for <65 years, 300 mg for >65 years)
Study: 26084792
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/day
Study: 29503404
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg/day
Study: 14666752
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment (eosin 5% and alcohol 95%)
Study: 8625054
Drug: Metoclopramide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (0.5 mg/kg) plus methylprednisolone (125 mg)
Study: 8625054
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg) orally
Study: 8625054
Drug: Granisetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (1 mg) orally plus methylprednisolone (125 mg)
Study: 2285628
Drug: Felodipine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine, 10 mg twice daily
Study: 7173301
Drug: Prednisolone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (8 mg/day)
Study: 7173301
Drug: Betamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (1 mg/day)
Study: 31996940
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg per 70-kg body weight dose of nicotine delivered over 1 min
Study: 31996940
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg per 70-kg body weight dose of nicotine delivered over 5 min
Study: 31996940
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg per 70-kg body weight dose of nicotine delivered over 10 min
Study: 23512260
Drug: Protocol 1
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1 (P1) - customized contrast dose based on time-attenuation response (0.3 ml/kg body weight)
Study: 23512260
Drug: Protocol 2
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 2 (P2) - tailored contrast dose based on body weight (0.7 ml/kg body weight)
Study: 22412028
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) administration
Study: 20150524
Drug: CIC 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC 160 µg BID (ex actuator)
Study: 20150524
Drug: CIC 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC 320 µg BID (ex actuator)
Study: 20150524
Drug: FP 220
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 220 µg BID (ex actuator)
Study: 20150524
Drug: FP 440
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 440 µg BID (ex actuator)
Study: 14696789
Drug: Furoxime (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furoxime (250 mg)
Study: 14696789
Drug: Zinnat (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinnat (250 mg)
Study: 10792119
Drug: Levosulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (25 mg t.d.s.)
Study: 12197843
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg t.d.s.)
Study: 7102580
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluoride supplement in divided doses with meals
Study: 7102580
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with basal diets containing 0.4 mg fluoride per day
Study: 7102580
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fluoride supplement
Study: 29096678
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered alteplase
Study: 26416029
Drug: Parent-Child Interaction
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-Child Interaction Therapy (EBT)
Study: 23415985
Drug: Medication combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication combined with chewing gum
Study: 21978087
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy in addition to routine nursing care
Study: 19303969
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin treatment (3 to 4 injections of insulin daily)
Study: 19303969
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin treatment plus an additional day per week of 3 intravenous pulses over an 8‐hour period
Study: 7923312
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine 200 mg (IBL 200)
Study: 7923312
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg (ASA 500)
Study: 2971512
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent clindamycin phosphate gel
Study: 2971512
Drug: 1 percent
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin 0.1 Percent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 percent clindamycin phosphate solution
Study: 2971512
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel vehicle)
Study: 23294132
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion
Study: 22708640
Drug: Nebivolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol (5 mg daily)
Study: 21536983
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (50 to 100 mg daily)
Study: 19561368
Drug: Virtual-reality-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual-reality-based exercise bike therapy
Study: 19561368
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation therapy without virtual-reality equipment
Study: 11590875
Drug: 5.2 g
Normalized name: Veltassa 25.2 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.2 g n‐3 PUFA daily for 12 weeks